Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Dec
04
Today In Oncology
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening
AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Survey Finds Global Embrace of Integrative Cancer Care
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo